Cancer treatment: at what cost?

Abstract

Nursing and Residential CareVol. 17, No. 3 EditorialCancer treatment: at what cost?Beverley AndersonBeverley AndersonSearch for more papers by this authorBeverley AndersonPublished Online:18 Feb 2015https://doi.org/10.12968/nrec.2015.17.3.173AboutSectionsView articleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareShare onFacebookTwitterLinked InEmail View article References Aapro MS (2012) Management of advanced prostate cancer in senior adults: the new landscape. Oncologist 17(Suppl 1): 16–22 Crossref, Google ScholarAttard G, Reid AHM, Yap TA et al. (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26(28): 4563–71. doi: https://doi.org/10.1200/JCO.2007.15.9749 Crossref, Google ScholarCancer Research UK (2011) Where did abiraterone come from? http://tinyurl.com/mg39ml9 (accessed 27 January 2015) Google ScholarCancer Research UK (2014) Prostate cancer. http://tinyurl.com/l7aru6y (accessed 27 January 2015) Google Scholarde Bono JS, Logothetis CJ, Molina A, Fizazi K et al. (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21): 1995–2005. doi: https://doi.org/10.1056/NEJMoa1014618 Crossref, Google ScholarFizazi K, Scher HI, Molina A, Logothetis CJ et al. (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13(10): 983–92. doi: https://doi.org/10.1016/S1470-2045(12)70379-0 Crossref, Google ScholarGravanis I, Lopez AS, Hemmings RJ, Jiménez JC et al. (2013) The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 18(9): 1032–42. doi: https://doi.org/10.1634/theoncologist.2013-0092 Crossref, Google ScholarLogothetis CJ, Basch E, Molina A, Fizazi K et al. (2012) Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 13(12): 1210–7. doi: https://doi.org/10.1016/S1470-2045(12)70473-4 Crossref, Google ScholarMacmillan Cancer Support (2014) Abiraterone acetate (Zytiga). http://tinyurl.com/p6b5apk (accessed 27 January 2015) Google ScholarMulders PFA, Molina A, Marberger M, Saad F et al. (2014) Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. Eur Urol 65(1): 875–83. doi: https://doi.org/10.1016/j.eururo.2013.09.005 Crossref, Google ScholarNational Cancer Institute (2012) Abiraterone Improves Survival in Metastatic Prostate Cancer. http://tinyurl.com/3m4orwt (accessed 27 January 2015) Google ScholarNational Institute of Health and Care Excellence (2011) Prostate cancer (metastatic, hormone relapsed, not treated with chemotherapy) – abiraterone acetate (with prednisolone) [ID503]: appraisal consultation document. http://tinyurl.com/nvx4tgv (accessed 27 January 2015) Google ScholarNational Institute of Health and Care Excellence (2014a) Prostate Cancer: diagnosis and treatment, NICE Clinical Guideline 175. http://tinyurl.com/pu6ccrm (accessed 27 January 2015) Google ScholarNational Institute of Health and Clinical Excellence (2014b) NICE appraisal of earlier treatment with abiraterone for prostate cancer. http://tinyurl.com/kmhrnz7 (accessed 27 January 2015) Google ScholarParker C, Sartor O (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 365(8): 767. doi: https://doi.org/10.1056/NEJMc1107198#SA3 Google ScholarPezaro CJ, Mukherji D, De Bono JS (2012) Abiraterone acetate: redefining hormone treatment for advanced prostate cancer. Drug Discov Today 17(5–6): 221–6. doi: https://doi.org/10.1016/j.drudis.2011.12.012 Crossref, Google ScholarProstate Cancer UK (2014) Abiraterone should definitely be an option for men who haven't had chemotherapy. http://tinyurl.com/k7b9dy9 (accessed 27 January 2015) Google ScholarRathkopf DE, Smith MR, De Bono JS et al. (2013) Updated interim analysis of COU-AA-302, a randomized phase III study of abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy. http://tinyurl.com/pr5ocav (accessed 27 January 2015) Google ScholarScher, HI., Logothetis, C., Molina, A., Goodman, OB., Sternberg, CN., Chi, KN., Kheoh, TS., Itagg, CM., Fizazi, de Bono, JS. et al. (2010) Improved Survival outcomes in clinically relevant patient subgroups from COU-AA-301, a phase III study of abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy, http://tinyurl.com/oph44n5 (accessed 27 January 2015) Google ScholarSmith R (2014) Prostate cancer patients ‘unjustly’ denied drug, The Telegraph. http://tinyurl.com/pvchebo (accessed 27 January 2015) Google ScholarThe Institute of Cancer Research (2014a) Abiraterone: a story of scientific innovation and commercial partnership. http://tinyurl.com/m2ehlpy (accessed 27 January 2015) Google ScholarThe Institute of Cancer Research (2014b) NICE pauses abiraterone decision for further price discussions. http://tinyurl.com/oeg3s5c (accessed 27 January 2015) Google Scholar FiguresReferencesRelatedDetailsCited byA Perspective on Uro-Oncology Management and the Macmillan Uro-Oncology CNS (MUCNS) Role in this Management23 March 2022 2 March 2015Volume 17Issue 3ISSN (print): 1465-9301ISSN (online): 2052-2932 Metrics History Published online 18 February 2015 Published in print 2 March 2015 Information© MA Healthcare LimitedPDF download